Incyte vs Medpace
INCY and MEDP side by side, both in engineering, accounting, research, management, and related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INCY and MEDP compare
Incyte is the larger company, worth 1.3 times as much as Medpace ($24.4B against $18.2B).
On earnings, Medpace is cheaper: it trades at 38.2× trailing earnings, against 64.0× for Incyte.
Incyte grew revenue faster over the last twelve months (24.9% versus 24.7% for Medpace).
Medpace keeps more of each dollar of sales as profit, with a net margin of 17.7% compared with 6.7% at Incyte.
Medpace scores higher on the StockData Score (15 against 13 for Incyte), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INCY | MEDP |
|---|---|---|
| Size and price | ||
| Market cap | $24.4B | $18.2B |
| Share price | $120.39 | $652.01 |
| Change, 1 year | 33.5% | 11.5% |
| Change, 5 years | 77.4% | 189% |
| Beta (5Y) | 0.45 | 1.39 |
| Employees | 2,844 | 6,200 |
| StockData Score | ||
| Total score | 13 | 15 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 3 | 4 (better) |
| Performance score | 3 | 6 (better) |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 64.0× | 38.2× (better) |
| P/S | 4.1× (better) | 6.5× |
| P/B | 4.3× (better) | 41.9× |
| EV/EBITDA | 29.1× (better) | 30.3× |
| P/FCF | – | 25.8× |
| PEG | 1.04 (better) | 1.36 |
| FCF yield | – | 3.9% |
| Fair value | $66.29 | $430.99 |
| Margin of safety | −81.6% | −51.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 24.9% (better) | 24.7% |
| Revenue growth, 5Y average | 14.0% | 22.3% (better) |
| Net income growth (TTM) | −66.1% | 17.5% (better) |
| EPS growth (TTM) | −68.2% | 26.8% (better) |
| EPS growth, 5Y average | – | 31.8% |
| Profitability | ||
| Gross margin | 92.7% | – |
| Operating margin | 10.4% | 21.0% (better) |
| Net margin | 6.7% | 17.7% (better) |
| FCF margin | – | 25.4% |
| Return on equity | 7.8% | 162% (better) |
| Return on invested capital | 13.9% | 1674% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | 268× | – |
| Current ratio | 3.84 (better) | 0.73 |
| Altman Z-score | 10.75 (better) | 8.44 |
| Piotroski F-score | 8 (better) | 6 |
| Dividends and buybacks | ||
| Buyback yield | – | 1.6% |
| Shareholder yield | 0.00% | 1.6% (better) |
| Ownership | ||
| Held by institutions | 100.0% | 88.5% |
| Held by insiders | 33.4% | 20.1% |
| Insider net buying, 12 months | −$58.0M (better) | −$409M |
| Superinvestors holding | – | 2 |
| Short interest, % of float | 7.4% | 7.2% |
Go deeper
- INCY stock overview
- INCY income statement
- INCY valuation and score
- MEDP stock overview
- MEDP income statement
- MEDP valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.